Dr. John Cush RheumNow
3 years 10 months ago
PSOAS study of 354 with long-standing ankylosing spondylitis & SI radiographic changes; but 23 lacked syndesmophytes. Lack of fusion was more likely in women & w/younger age of Sx onset. All were B27+, thus B27 may be assoc w/ SI dz, not spinal dz. https://t.co/EpDW6wTZNr https://t.co/IHRvdkDiaD
Dr. John Cush RheumNow
3 years 10 months ago
Listen to the FDA Drug Safety Podcast (for HCPs). On the Risk of Serious Adverse events with JAK Inhibitors (based on their HCP safety alert from 9/21/2021). 4 min long, basic info, not alot of depth...but its from the FDA. https://t.co/0Hns5bDU2A https://t.co/mRKi8NEKGW
EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.
The revision included 15 recommendations in total. Of these, 11 either remained the same from earlier editions or involved minor wording changes. Two, however, differed substantially, and two others were entirely new.
Newly released guidance for defining remission in rheumatoid arthritis (RA) is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.
Dr. John Cush RheumNow
3 years 10 months ago
Pre and post-COVID-19 assessment of 78 FM pts by Fibromyalgia Impact Questionnaire-Revised (FIQR). While COVID affected FM pts, there was no statistically significant change in FIQR scores (65% had no improvement or deterioration on FIQR) https://t.co/S1clBCvzWm https://t.co/ZApmgvKM2c
Dr. John Cush RheumNow
3 years 10 months ago
2022 ASAS-EULAR Guidelines for Axial Spondyloarthritis
Assessment of SpondyloArthritis international Society (ASAS) and EULAR have published their 2022 update and recommendations for the management of axial spondyloarthritis (axSpA).
https://t.co/oX8oXm0adU https://t.co/JyzT6VxMSQ
Dr. John Cush RheumNow
3 years 10 months ago
TNF inhibitors Dont Increase Cancer Risk! 4592 RA pts:TNFi Rx (2296) vs matched DMARD Rx (2296) pts. TNFi had a lower cancer risk than DMARD Rx (IR 6.5 vs. 15.6 /1000PYs]). TNFi had Lower HR GI CA (0.432), breast CA (0.146), GU CA (0.220) https://t.co/F5ToHLJULn
Dr. John Cush RheumNow
3 years 10 months ago
Mayo Clinic Biobank matched case-control study (1:3) of 212 incident RA cases Active work physical activity lowered risk of RA (aOR 3.00), while 3-5 servings high-fat foods, fruits/vegetables lowered risk (OR 0.45; OR 0.54). https://t.co/AAQ1nRfJXq https://t.co/72yLQUllDV
Dr. John Cush RheumNow
3 years 10 months ago
1915 Rheumatic (RMD)pts w/ COVID (42% RA. 15% SLE, 1/2 comorbidities); Outcomes: 28% hospitalized, 8% to ICU & 4% died from COVID-19. Poor COVID-19 outcomes seen w/ age, male, Hi Dz activity, steroids & RTX, & 1+ comorbidity https://t.co/ztBiJc9nxV https://t.co/RVOKyjseFJ
Dr. John Cush RheumNow
3 years 10 months ago
Acute Hot Joint? A systematic review of 49 articles, looking at SF & serum markers to distinguish septic vs non-septic joints. They found 8 discriminatory SF tests w/ WBC esterase highest sensitivity (0.94)& specificity (0.74) https://t.co/SamgBwyBrL https://t.co/t9JOiRMMHI
Dr. John Cush RheumNow
3 years 10 months ago
#Gout clinic study of 223 gout pts on allopurinol ≥300 mg compared Pt & MD gout control assessments (0-10). Better agreement & higher scores seen w/o flares (3 or 12 mos) & SUA w/in target. Disagreement (22%) w/ recent flares & tophi https://t.co/a0WsMLvfYk https://t.co/zZwV4XVJzS
Dr. John Cush RheumNow
3 years 10 months ago
Metanalysis of emergency department Rx of opioids for MSK pain - 42 articles, 6128 pts - Short term (2hr) benefits of ED opioids were statistically but not clinically more effective than PBO or Tylenol, but not better than NSAIDs. Safety uncertain. https://t.co/Lmf8Ubuacw https://t.co/prP6Ei3wqA
Dr. John Cush RheumNow
3 years 10 months ago
Will we see you there? #ACR2022
What are you most looking forward to on the agenda? https://t.co/6nUMBmqnTy
Dr. John Cush RheumNow
3 years 10 months ago
Predictors of serious infection (SIE) in SLE? A prior SIE conferred the highest risk of subsequent SIE. Study of 346 SLE pts shows SIE rate of 3.8/100 Pt-Yrs. Other risk factors:
Damage accrual, comorbidity, Dz activity, CTX use https://t.co/t65XzmFzQG https://t.co/78jiUnaq7d
Dr. John Cush RheumNow
3 years 10 months ago
Love the RheumNow podcast? Subscribe, rate and review!
Listen in the car, airplane, anywhere! We also reach more listeners through reviews from our users. Consider leaving a review!
https://t.co/QlcUIxqY8A https://t.co/k2ybeeYGz5
